SK50672005A3 - Prípravok imunoglobulínu a spôsob jeho prípravy - Google Patents

Prípravok imunoglobulínu a spôsob jeho prípravy Download PDF

Info

Publication number
SK50672005A3
SK50672005A3 SK5067-2005A SK50672005A SK50672005A3 SK 50672005 A3 SK50672005 A3 SK 50672005A3 SK 50672005 A SK50672005 A SK 50672005A SK 50672005 A3 SK50672005 A3 SK 50672005A3
Authority
SK
Slovakia
Prior art keywords
composition
polysorbate
amount
antibody
present
Prior art date
Application number
SK5067-2005A
Other languages
English (en)
Slovak (sk)
Inventor
David J. Burke
Shaun E. Buckley
Sherwood Russ Lehrman
Barbara Horsey O�Connor
James Callaway
Original Assignee
Elan Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32869424&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK50672005(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Elan Pharmaceuticals, Inc. filed Critical Elan Pharmaceuticals, Inc.
Publication of SK50672005A3 publication Critical patent/SK50672005A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
SK5067-2005A 2003-02-10 2004-02-09 Prípravok imunoglobulínu a spôsob jeho prípravy SK50672005A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44581803P 2003-02-10 2003-02-10
PCT/US2004/003873 WO2004071439A2 (en) 2003-02-10 2004-02-09 Immunoglobulin formulation and method of preparation thereof

Publications (1)

Publication Number Publication Date
SK50672005A3 true SK50672005A3 (sk) 2006-03-02

Family

ID=32869424

Family Applications (1)

Application Number Title Priority Date Filing Date
SK5067-2005A SK50672005A3 (sk) 2003-02-10 2004-02-09 Prípravok imunoglobulínu a spôsob jeho prípravy

Country Status (29)

Country Link
US (7) US20050053598A1 (de)
EP (4) EP1592440A4 (de)
JP (3) JP4728948B2 (de)
KR (1) KR20050110628A (de)
CN (2) CN1771053B (de)
AR (1) AR043144A1 (de)
AU (2) AU2004210679A1 (de)
CA (1) CA2515444C (de)
CL (1) CL2004000224A1 (de)
CY (2) CY1120574T1 (de)
DK (2) DK2236154T3 (de)
ES (1) ES2819011T3 (de)
HK (1) HK1182021A1 (de)
HU (1) HUE051878T2 (de)
IL (1) IL170008A (de)
MX (1) MXPA05008409A (de)
MY (1) MY162623A (de)
NO (1) NO346070B1 (de)
PE (1) PE20050190A1 (de)
PT (2) PT2236154T (de)
RU (1) RU2358763C2 (de)
SI (2) SI3417875T1 (de)
SK (1) SK50672005A3 (de)
TR (1) TR201808801T4 (de)
TW (1) TWI367766B (de)
UA (1) UA82685C2 (de)
UY (1) UY28184A1 (de)
WO (1) WO2004071439A2 (de)
ZA (1) ZA200506159B (de)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0307975A (pt) * 2002-02-25 2005-01-11 Elan Pharm Inc Métodos para reduzir cronicamente a inflamação patológica em um paciente e para determinar a eficácia de um regime de administração crÈnica para tratar inflamação patológica em um indivìduo, composição e terapia combinada para tratamento crÈnico de inflamação patológica em um paciente e uso de um inibidor de alfa-4-integrina
EP1545611B1 (de) * 2002-09-06 2016-11-09 Alexion Pharmaceuticals, Inc. Verfahren zur behandlung von asthma mit antikörpern zur komplementierung von komponente c5
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
US9415102B2 (en) * 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
WO2004071439A2 (en) * 2003-02-10 2004-08-26 Elan Pharmaceuticals, Inc. Immunoglobulin formulation and method of preparation thereof
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US8277810B2 (en) * 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
US7619066B2 (en) * 2004-04-02 2009-11-17 Amgen Inc. IL-1ra variants
CA2478458A1 (en) * 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP1827491A4 (de) * 2004-11-19 2010-07-14 Biogen Idec Inc Behandlung von multipler sklerose
WO2006096490A2 (en) * 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc ANTI-MAdCAM ANTIBODY COMPOSITIONS
MX2007014148A (es) 2005-05-19 2008-01-11 Amgen Inc Composiciones y metodos para incrementar la estabilidad de anticuerpos.
AR057807A1 (es) * 2005-09-12 2007-12-19 Novimmune Sa Formulaciones de anticuerpo anti-cd3
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
MX2008008621A (es) 2005-12-29 2008-11-27 Centocor Inc Anticuerpos anti-il-23 humanos, composiciones, metodos y usos.
DK2359834T5 (en) 2006-03-15 2017-02-06 Alexion Pharma Inc Treatment of paroxysmal nocturnal hemoglobinuria patients with a complement inhibitor
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
JP2010504361A (ja) * 2006-09-25 2010-02-12 メディミューン，エルエルシー 安定した抗体製剤およびその使用
US20080112953A1 (en) * 2006-10-06 2008-05-15 Amgen Inc. Stable formulations
EP2094247B1 (de) 2006-10-20 2022-06-29 Amgen Inc. Stabile polypeptid-formulierungen
PE20081610A1 (es) * 2007-01-09 2008-12-09 Wyeth Corp Formulaciones de anticuerpos anti-il-13 y usos de los mismos
ATE535157T1 (de) * 2007-02-12 2011-12-15 Lassaad Boujbel Sterile sucralose-lösung ohne konservierungsmittel und dessen herstellungsverfahren
WO2008157356A2 (en) * 2007-06-14 2008-12-24 Biogen Idec Ma Inc. Antibody formulations
US20090208492A1 (en) * 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
WO2009003010A2 (en) * 2007-06-25 2008-12-31 Becton, Dickinson And Company Methods for evaluating the aggregation of a protein in a suspension including organopolysiloxane and medical articles coated with organopolysiloxane containing a protein solution
ES2543735T3 (es) * 2007-10-22 2015-08-21 Becton Dickinson And Company Artículos médicos revestidos con organopolisiloxano que contienen una disolución de proteína y un tensioactivo no iónico
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
TWI489994B (zh) 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
WO2009124294A2 (en) * 2008-04-05 2009-10-08 Lpath, Inc. Pharmaceutical compositions for binding sphingosine-1-phosphate
PT2271382E (pt) 2008-04-15 2013-05-07 Grifols Therapeutics Inc Ultrafiltração em dois andares/diafiltração
WO2010027766A1 (en) 2008-08-27 2010-03-11 Schering Corporation Lyophilized formulatons of engineered anti-il-23p19 antibodies
TWI516501B (zh) * 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
CN102301235B (zh) * 2008-11-28 2014-11-19 Abbvie公司 稳定的抗体组合物和用于稳定其的方法
WO2010077045A2 (en) * 2008-12-29 2010-07-08 Samyang Corporation Pharmaceutical composition of lyophilized formulation and preparation method of the same
FR2940617B1 (fr) * 2008-12-30 2012-04-20 Fractionnement Et Des Biotechonologies Lab Franc Composition d'immunoglobulines g
CA2758548A1 (en) * 2009-04-17 2010-10-21 Biogen Idec Ma Inc. Compositions and methods to treat acute myelogenous leukemia
JP2012526121A (ja) * 2009-05-04 2012-10-25 アボツト・バイオテクノロジー・リミテツド ヒト抗ｔｎｆアルファ抗体の安定した高蛋白質濃度製剤
CA2774053C (en) * 2009-09-17 2015-04-28 Baxter Healthcare, S.A. Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
EP3708190A1 (de) * 2010-02-26 2020-09-16 Novo Nordisk A/S Stabile, antikörperhaltige zusammensetzungen
PT3202789T (pt) 2010-04-16 2020-06-16 Biogen Ma Inc Anticorpos anti-vla-4
US20130136733A1 (en) 2010-05-28 2013-05-30 Novo Nordisk A/S Stable Multi-Dose Compositions Comprising an Antibody and a Preservative
HUE048398T2 (hu) 2010-06-04 2020-07-28 Wyeth Llc Vakcinakészítmények
EP2600901B1 (de) 2010-08-06 2019-03-27 ModernaTX, Inc. Pharmazeutische zusammensetzungen enthaltenbearbeitete nukleinsäuren und ihre medizinische verwendung
SG188487A1 (en) 2010-09-17 2013-05-31 Baxter Int Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral ph
ES2737960T3 (es) 2010-10-01 2020-01-17 Modernatx Inc Nucleósidos, nucleótidos y ácidos nucleicos modificados y sus usos
US20130337470A1 (en) 2010-10-25 2013-12-19 Biogen Idec Ma Inc. METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMadCAM LEVELS
MX344727B (es) 2010-11-11 2017-01-05 Abbvie Biotechnology Ltd Formulaciones liquidas de anticuerpos anti-tnf-alfa de alta concentracion mejoradas.
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
TR201810298T4 (tr) 2011-03-31 2018-08-27 Merck Sharp & Dohme İnsan programlı ölüm reseptörü PD-1'e karşı antikorların stabil formülasyonları ve ilgili tedaviler.
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
EP2714076A1 (de) * 2011-05-26 2014-04-09 GlaxoSmithKline Biologicals S.A. Inaktivierter dengue-virusimpfstoff
JP6463968B2 (ja) * 2011-07-01 2019-02-06 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． アルギニンを含まない腫瘍壊死因子受容体：ｆｃ融合ポリペプチド組成物およびその使用方法
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3682905B1 (de) 2011-10-03 2021-12-01 ModernaTX, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
EP2791160B1 (de) 2011-12-16 2022-03-02 ModernaTX, Inc. Modifizierte mrna zusammensetzungen
MX357393B (es) * 2012-01-23 2018-07-06 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti - ang2.
JP6265970B2 (ja) * 2012-03-26 2018-01-24 サノフイ 安定なＩｇＧ４に基づく結合剤の製剤
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
AU2013243948A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
AR091902A1 (es) 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
EP2727602A1 (de) * 2012-10-31 2014-05-07 Takeda GmbH Verfahren zur Herstellung einer hochkonzentrierten Flüssigkeitsformulierung eines Antikörpers
EP4074834A1 (de) 2012-11-26 2022-10-19 ModernaTX, Inc. Am kettenende modifizierte rna
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
JP6463361B2 (ja) 2013-09-08 2019-01-30 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． 第ｖｉｉｉ因子両性イオンポリマーコンジュゲート
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
CA2926218A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
KR102372245B1 (ko) 2013-11-21 2022-03-08 젠맵 에이/에스 항체-약물 접합체 동결건조 제제
US9932591B2 (en) 2013-12-18 2018-04-03 University Of Delaware Reduction of lipase activity in product formulations
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
JP6849590B2 (ja) 2014-10-17 2021-03-24 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． ブチリルコリンエステラーゼ両性イオン性ポリマーコンジュゲート
AR104847A1 (es) 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
US20210322549A1 (en) * 2015-07-17 2021-10-21 Coherus Biosciences, Inc. Stable Aqueous Formulations of Natalizumab
US10484453B2 (en) * 2015-07-29 2019-11-19 Xerox Corporation System and method for printing documents using print hardware and automatic context inference
KR20180104635A (ko) 2015-12-30 2018-09-21 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
SG11201805534TA (en) 2016-01-13 2018-07-30 Genmab As Formulation for antibody and drug conjugate thereof
WO2017137570A1 (en) 2016-02-10 2017-08-17 Becton Dickinson France Method to evaluate the stability of a protein-based formulation
EP3541413A2 (de) 2016-11-21 2019-09-25 Polpharma Biologics S.A. Wässrige pharmazeutische formulierungen
US11845798B2 (en) 2017-05-02 2023-12-19 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
ES2938608T3 (es) * 2017-09-20 2023-04-13 Tillotts Pharma Ag Método para preparar una forma farmacéutica sólida que comprende anticuerpos mediante granulación en húmedo, extrusión y esferonización
CN111683678B (zh) 2017-12-06 2024-01-26 默沙东有限责任公司 包含肺炎链球菌多糖蛋白缀合物的组合物及其使用方法
US20190194277A1 (en) * 2017-12-08 2019-06-27 Argenx Bvba Use of fcrn antagonists for treatment of generalized myasthenia gravis
US20210031012A1 (en) 2018-01-26 2021-02-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
EP3761953A1 (de) 2018-03-08 2021-01-13 Coherus Biosciences, Inc. Stabile wässrige formulierungen von aflibercept
US11426446B2 (en) 2018-03-08 2022-08-30 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
AU2019251452A1 (en) * 2018-04-10 2020-11-26 Dr. Reddy's Laboratories Limited Stable antibody formulation
WO2019198100A1 (en) * 2018-04-10 2019-10-17 Dr. Reddy's Laboratories Limited Antibody formulation
US20220257600A1 (en) 2018-06-20 2022-08-18 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
EP3810095A1 (de) 2018-06-20 2021-04-28 Progenity, Inc. Behandlung einer erkrankung des magen-darm,-traktes mit einem tnf-inhibitor
EP3810268A1 (de) 2018-06-20 2021-04-28 Progenity, Inc. Behandlung einer erkrankung des magen-darm-traktes mit einem il-12/il-23-inhibitor
EP3810085A1 (de) 2018-06-20 2021-04-28 Progenity, Inc. Behandlung der erkrankung des gastrointestinaltraktes mit einem integrin-inhibitor
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US11738068B2 (en) 2018-06-25 2023-08-29 Jcr Pharmaceuticals Co., Ltd. Protein-containing aqueous liquid formulation
MA55149A (fr) 2018-11-20 2021-09-29 Janssen Biotech Inc Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23
TWI788610B (zh) 2018-12-19 2023-01-01 美商默沙東有限責任公司 包含肺炎鏈球菌多醣-蛋白質結合物之組合物及其使用方法
US11780911B2 (en) 2019-05-23 2023-10-10 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
MA56102A (fr) * 2019-06-07 2022-04-13 Argenx Bvba Formulations pharmaceutique d'inhibiteurs de fcrn appropriées pour une administration par voie sous-cutanée
AU2020291508A1 (en) * 2019-06-11 2022-01-06 Macrogenics, Inc. Pharmaceutical formulations of bi-specific diabodies and use of the same
WO2021050687A1 (en) 2019-09-10 2021-03-18 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
CN114786724A (zh) * 2019-12-16 2022-07-22 尼普洛株式会社 防聚集剂以及使用该防聚集剂的药物组合物和医疗用设备
JP2023512446A (ja) * 2020-01-13 2023-03-27 アプティーボ リサーチ アンド デベロップメント エルエルシー 治療的タンパク質の薬物送達システム構成要素への吸着を防ぐ方法および組成物
JP2023512991A (ja) * 2020-01-29 2023-03-30 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｌａｇ３抗体生成からの宿主細胞リパーゼの分離方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2508132C3 (de) * 1974-03-08 1980-10-16 Teijin Ltd., Osaka (Japan) Verfahren zur Herstellung von Humanimmunglobulin-Derivaten und parenteral applizierbare Lösung hiervon
US4362661A (en) * 1979-08-09 1982-12-07 Teijin Limited Immunoglobulin composition having a high monomer content, and process for production thereof
US4597966A (en) * 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
JPH03504499A (ja) * 1988-05-27 1991-10-03 セントカー・インコーポレーテツド 抗体試薬のための配合物
US5945098A (en) * 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US7435802B2 (en) * 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
CA2226575C (en) * 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
DE69810481T2 (de) 1997-06-13 2003-09-25 Genentech Inc Stabilisierte antikörperformulierung
DE19912637A1 (de) 1999-03-20 2000-09-21 Aventis Cropscience Gmbh 2,4-Diamino-1,3,5-triazine, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
IL145134A0 (en) 1999-03-25 2002-06-30 Knoll Gmbh Human antibodies that bind human il-12 and methods for producing
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
DE10013029A1 (de) * 2000-03-17 2001-09-20 Roehm Gmbh Mehrschichtige Arzneiform für die Colonfreigabe
US7288390B2 (en) * 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
MXPA02009478A (es) * 2001-01-31 2003-03-10 Roehm Gmbh Forma medicinal de multiples particulas que comrpende por lo menos dos formas de bolitas recubiertas de diferente manera.
DE10133394A1 (de) * 2001-07-13 2003-01-30 Merck Patent Gmbh Flüssige Formulierung enthaltend Cetuximab
JP4317010B2 (ja) * 2001-07-25 2009-08-19 ピーディーエル バイオファーマ，インコーポレイティド ＩｇＧ抗体の安定な凍結乾燥医薬製剤
KR101080021B1 (ko) * 2002-02-14 2011-11-04 추가이 세이야쿠 가부시키가이샤 항체함유 용액제제
BR0307975A (pt) * 2002-02-25 2005-01-11 Elan Pharm Inc Métodos para reduzir cronicamente a inflamação patológica em um paciente e para determinar a eficácia de um regime de administração crÈnica para tratar inflamação patológica em um indivìduo, composição e terapia combinada para tratamento crÈnico de inflamação patológica em um paciente e uso de um inibidor de alfa-4-integrina
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
WO2004071439A2 (en) * 2003-02-10 2004-08-26 Elan Pharmaceuticals, Inc. Immunoglobulin formulation and method of preparation thereof
US7807187B2 (en) 2003-05-13 2010-10-05 The University Of Massachusetts Endogenous adjuvant molecules and uses thereof
MXPA06008746A (es) 2004-02-06 2007-01-23 Elan Pharm Inc Metodos y composiciones para tratamiento de tumores y enfermedad metastatica.
MY162179A (en) 2004-04-01 2017-05-31 Elan Pharm Inc Steroid sparing agents and methods of using same
WO2008157356A2 (en) 2007-06-14 2008-12-24 Biogen Idec Ma Inc. Antibody formulations

Also Published As

Publication number Publication date
NO346070B1 (no) 2022-01-31
HK1182021A1 (en) 2013-11-22
US20120328614A1 (en) 2012-12-27
HUE051878T2 (hu) 2021-03-29
JP2014028831A (ja) 2014-02-13
KR20050110628A (ko) 2005-11-23
CA2515444C (en) 2014-04-01
PT3417875T (pt) 2020-08-24
ZA200506159B (en) 2006-10-25
ES2819011T3 (es) 2021-04-14
CN103040732A (zh) 2013-04-17
RU2005128280A (ru) 2006-06-10
UA82685C2 (uk) 2008-05-12
EP2236154A1 (de) 2010-10-06
UY28184A1 (es) 2004-09-30
US20150044206A1 (en) 2015-02-12
EP3417875B1 (de) 2020-06-17
JP2006517233A (ja) 2006-07-20
CN1771053B (zh) 2012-10-03
TWI367766B (en) 2012-07-11
US20210292419A1 (en) 2021-09-23
AU2010202254A1 (en) 2010-06-24
DK2236154T3 (en) 2018-06-25
EP2236154B1 (de) 2018-05-30
MXPA05008409A (es) 2005-10-05
US8349321B2 (en) 2013-01-08
EP1592440A2 (de) 2005-11-09
TW200505478A (en) 2005-02-16
US20050053598A1 (en) 2005-03-10
SI2236154T1 (en) 2018-08-31
EP3777880A1 (de) 2021-02-17
CL2004000224A1 (es) 2005-01-21
IL170008A (en) 2015-05-31
WO2004071439A3 (en) 2005-07-07
NO20054164L (no) 2005-09-07
CN103040732B (zh) 2015-04-01
US10954303B2 (en) 2021-03-23
DK3417875T3 (da) 2020-08-31
MY162623A (en) 2017-06-30
EP3417875A1 (de) 2018-12-26
RU2358763C2 (ru) 2009-06-20
AU2010202254B2 (en) 2012-02-23
US8815236B2 (en) 2014-08-26
US20130071386A1 (en) 2013-03-21
PT2236154T (pt) 2018-06-26
SI3417875T1 (sl) 2021-01-29
AR043144A1 (es) 2005-07-20
EP1592440A4 (de) 2007-07-11
US20180194843A1 (en) 2018-07-12
JP2011088913A (ja) 2011-05-06
CY1120574T1 (el) 2019-07-10
AU2004210679A1 (en) 2004-08-26
CY1123667T1 (el) 2022-03-24
PE20050190A1 (es) 2005-03-21
JP4728948B2 (ja) 2011-07-20
TR201808801T4 (tr) 2018-07-23
US20100021461A1 (en) 2010-01-28
CA2515444A1 (en) 2004-08-26
CN1771053A (zh) 2006-05-10
WO2004071439A2 (en) 2004-08-26
US8900577B2 (en) 2014-12-02

Similar Documents

Publication Publication Date Title
US20210292419A1 (en) Immunoglobulin formulation and method of preparation thereof
ES2676544T3 (es) Formulación de inmunoglobulina y procedimiento de preparación de la misma
US9216219B2 (en) Anti-BAFFR antibody formulation
AU2006211184B2 (en) Anti a beta antibody formulation
KR20100038100A (ko) 동결건조된 면역글로불린 제형 및 그의 제조 방법
AU2012202845B2 (en) Immunoglobulin formulation and method of preparation thereof
CA3235650A1 (en) Aqueous formulations of an anti-cd22 antibody and uses thereof

Legal Events

Date Code Title Description
TA4A Addition of inventor(s)
PC4A Assignment and transfer of rights

Owner name: BIOGEN IDEC INTERNATIONAL HOLDING LTD., HAMILT, BM

Free format text: FORMER OWNER: ELAN PHARMACEUTICALS, INC., CAMBRIDGE, MA, US

Effective date: 20141030

Owner name: BIOGEN IDEC MA INC., CAMBRIDGE, MASSACHUSETTS, US

Free format text: FORMER OWNER: BIOGEN IDEC INTERNATIONAL HOLDING LTD., HAMILTON HM EX, BM

Effective date: 20141030

TE4A Change of owner's address

Owner name: ELAN PHARMACEUTICALS, INC., CAMBRIDGE, MA, US

Effective date: 20141030

FC9A Refused patent application